Tempest Therapeutics
TPST
41 hedge funds and large institutions have $7.97M invested in Tempest Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 15 closing their positions.
18% less funds holding
Funds holding: 50 → 41 (-9)
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
64% less capital invested
Capital invested by funds: $21.9M → $7.97M (-$14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$884K |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$821K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$333K |
| 4 |
VF
Virtu Financial
New York
|
+$129K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5M |
| 2 |
Jennison Associates
New York
|
-$3.06M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$522K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$461K |
| 5 |
BCM
BBT Capital Management
Fort Worth,
Texas
|
-$355K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
51
BBT Capital Management
Fort Worth,
Texas
| – | -$355K | -87 | Closed |
|
52
Squarepoint
New York
| – | -$122K | -30 | Closed |
|
53
Goldman Sachs
New York
| – | -$97K | -24 | Closed |
|
|
AL
54
AJO LP
Philadelphia,
Pennsylvania
| – | -$86K | -21 | Closed |
|
|
ARTA
55
A.R.T. Advisors
New York
| – | -$51K | -13 | Closed |
|
|
TSS
56
Two Sigma Securities
New York
| – | -$48K | -12 | Closed |
|
|
SKK
57
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| – | -$28K | -7 | Closed |
|
|
SIP
58
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$14K | -3 | Closed |
|
59
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8K | -2 | Closed |
|
|
LTFS
60
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$3K | -1 | Closed |
|
|
MA
61
MUFG Americas
New York
| – | -$4K | -1 | Closed |
|
TPST Hedge Fund Activity: Q1 2018 in Review
41 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2018, worth a combined $7.97M — down 64% from $21.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TPST and 6 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Sabby Management, adding an estimated $884K. The largest seller was Fidelity Investments, exiting entirely with an estimated $5M sold.
- 41 institutional investors held Tempest Therapeutics (TPST) as of Q1 2018, down from 50 in Q4 2017.
- Funds reported $7.97M of Tempest Therapeutics stock for Q1 2018, down 64% quarter-over-quarter.
- 6 funds opened new Tempest Therapeutics positions in Q1 2018 and 15 closed out, a net change of -9 holders.
- The largest Tempest Therapeutics buyer in Q1 2018 was Sabby Management, an estimated $884K added.
- The largest Tempest Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $5M sold.
Based on aggregated 13F filings for Q1 2018.